Plain-English translation of NCT07213440 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are looking for early biological markers—measurable signs in blood, tears, and urine—that could help diagnose ALS before symptoms appear or very early in the disease. Right now, ALS is often diagnosed only after significant damage has occurred, which means patients miss the window for treatments that work best early on. This study compares samples from three groups: people who carry ALS-causing genetic mutations but have no symptoms yet, healthy people without the mutation, and people with very early ALS symptoms—to create a 'molecular fingerprint' that could spot ALS much sooner.
ALS is a rapidly progressive disease, and by the time most people are diagnosed, the disease is already advanced. If doctors could identify ALS years earlier—even before symptoms start—patients could begin disease-slowing treatments when they're most effective.
You likely qualify if…
You likely don't qualify if…
This is a single-visit observational study—you are not taking any medication or receiving a treatment. Instead, you will have a health evaluation and will be asked to provide three types of samples: a blood sample, tears (collected with a special swab), and a urine sample. These samples will be analyzed for biological markers that may help researchers understand ALS and develop better early diagnosis methods. The whole process typically takes a few hours at the research site.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
France